Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(2):796-816. doi:10.7150/thno.67375 This issue Cite

Review

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle

Yue Huang1,2,3, Jessica C. Hsu1,4, Hyun Koo2,3, David P. Cormode1,4✉

1. Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2. Biofilm Research Labs, Levy Center for Oral Health, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA
3. Department of Preventive & Restorative Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA
4. Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA

✉ Corresponding authors: david.cormodeupenn.edu, koohyedu

Citation:
Huang Y, Hsu JC, Koo H, Cormode DP. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics 2022; 12(2):796-816. doi:10.7150/thno.67375. https://www.thno.org/v12p0796.htm
Other styles

File import instruction

Abstract

Graphic abstract

Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities.

Keywords: ferumoxytol, magnetic resonance imaging (MRI), iron deficiency, nanozyme, drug delivery

Citation styles

APA
Huang, Y., Hsu, J.C., Koo, H., Cormode, D.P. (2022). Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics, 12(2), 796-816. https://doi.org/10.7150/thno.67375.

ACS
Huang, Y.; Hsu, J.C.; Koo, H.; Cormode, D.P. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics 2022, 12 (2), 796-816. DOI: 10.7150/thno.67375.

NLM
Huang Y, Hsu JC, Koo H, Cormode DP. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics 2022; 12(2):796-816. doi:10.7150/thno.67375. https://www.thno.org/v12p0796.htm

CSE
Huang Y, Hsu JC, Koo H, Cormode DP. 2022. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. Theranostics. 12(2):796-816.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use